“`html
Revive Therapeutics (OTCQB: RVVTF) has completed the first tranche of its private placement offering, raising $60,900 through the issuance of 2.9 million units at $0.021 per unit. Additionally, the company settled $67,400 in debt through the issuance of 3.2 million units at the same price.
Each unit consists of one common share and one warrant exercisable at $0.05 for 36 months. The company also issued 100,000 compensation options to an investment dealer. The proceeds will be used for working capital and trade payables, with securities subject to a hold period until December 9, 2025.
Revive Therapeutics (OTCQB: RVVTF) ha completato la prima tranche del suo collocamento privato, raccogliendo $60,900 con l’emissione di 2,9 milioni di unità a $0.021 per unità. Inoltre, la società ha estinto debiti per $67,400 mediante l’emissione di 3,2 milioni di unità allo stesso prezzo.
Ciascuna unità comprende una azione comune e un warrant esercitabile a $0.05 per 36 mesi. La società ha altresì emesso 100.000 opzioni di compenso a un intermediario finanziario. I proventi saranno destinati al capitale circolante e al pagamento dei debiti commerciali; i titoli saranno soggetti a un periodo di lock-up fino al 9 dicembre 2025.
Revive Therapeutics (OTCQB: RVVTF) completó la primera tranche de su colocación privada, recaudando $60,900 mediante la emisión de 2,9 millones de unidades a $0.021 por unidad. Además, la compañía saldó $67,400 de deuda mediante la emisión de 3,2 millones de unidades al mismo precio.
Cada unidad consta de una acción ordinaria y un warrant ejercitable a $0.05 durante 36 meses. La compañía también emitió 100,000 opciones de compensación a un intermediario de inversión. Los fondos se destinarán a capital de trabajo y cuentas por pagar; los valores estarán sujetos a un periodo de retención hasta el 9 de diciembre de 2025.
Revive Therapeutics (OTCQB: RVVTF)가 사모 발행의 첫 번째 트랜치를 완료해 2,900,000유닛을 주당 $0.021에 발행하여 $60,900을 조달했습니다. 또한 동일한 가격으로 3,200,000유닛을 발행해 $67,400의 부채를 상계했습니다.
각 유닛은 보통주 1주와 행사가 $0.05, 만기 36개월인 워런트 1개로 구성됩니다. 회사는 또한 투자 딜러에게 100,000개의 보수용 옵션을 발행했습니다. 수익금은 유동 자금과 매입 채무 상환에 사용되며, 해당 증권은 2025년 12월 9일까지 유통제한(락업)이 적용됩니다.
Revive Therapeutics (OTCQB: RVVTF) a réalisé la première tranche de son placement privé, levant $60,900 par l’émission de 2,9 millions d’unités à $0.021 l’unité. En outre, la société a apuré $67,400 de dettes par l’émission de 3,2 millions d’unités au même prix.
Chaque unité comprend une action ordinaire et un warrant exerçable à $0.05 pendant 36 mois. La société a également émis 100 000 options de rémunération à un intermédiaire financier. Les fonds seront utilisés pour le fonds de roulement et le paiement des fournisseurs ; les titres sont soumis à une période de blocage jusqu’au 9 décembre 2025.
Revive Therapeutics (OTCQB: RVVTF) hat die erste Tranche seiner Privatplatzierung abgeschlossen und dabei $60,900 durch die Ausgabe von 2,9 Millionen Einheiten zu $0.021 pro Einheit eingenommen. Zusätzlich hat das Unternehmen $67,400 an Verbindlichkeiten durch die Ausgabe von 3,2 Millionen Einheiten zum gleichen Preis beglichen.
Jede Einheit besteht aus einer Stammaktie und einem Warrant, der zu $0.05 innerhalb von 36 Monaten ausübbar ist. Das Unternehmen hat außerdem 100.000 Vergütungsoptionen an einen Investment-Dealer ausgegeben. Die Erlöse werden für das Betriebskapital und Verbindlichkeiten aus Lieferungen und Leistungen verwendet; die Wertpapiere unterliegen einer Sperrfrist bis zum 9. Dezember 2025.
Positive
- Debt settlement of $67,400 preserves cash for operations
- Additional funding of $60,900 secured through private placement
- Warrants provide potential for future capital at $0.05 per share
Negative
- Significant dilution through issuance of over 6.1 million new units
- Low unit pricing at $0.021 indicates weak market position
- Additional dilution possible through compensation options and warrants
08/11/2025 – 07:28 PM
**Revive Therapeutics (RVVTF) Secures $60,900 in Private Placement, Settles Debt**
TORONTO – Revive Therapeutics Ltd. (OTCQB: RVVTF), a life sciences company focused on innovative therapeutics, announced the closing of the first tranche of its private placement, injecting $60,900 into its coffers. The company issued 2.9 million units at a price of $0.021 each, according to a recent press release. In a parallel move, Revive settled $67,400 in existing debt by issuing 3.2 million units at the same price – a strategic maneuver industry observers suggest aims to bolster its balance sheet amidst ongoing operations.
Each unit encompasses a common share and a warrant. The warrants grant holders the right to purchase a common share at $0.05 within a 36-month period, potentially offering future upside and diluting existing shareholders if exercised. The deal also includes the issuance of 100,000 compensation options to an investment dealer involved in the offering.
Revive plans to channel the fresh capital into working capital and settling outstanding trade payables. The securities issued are subject to a hold period, restricting trading activity until December 9, 2025.
Analysts note that this financing round reflects the challenges faced by smaller biotech firms in securing funding, opting for dilutive measures to maintain operational liquidity. The low unit price of $0.021 underscores this point, despite the potential upside offered by the warrants.
Revive Therapeutics is betting on its pipeline of therapeutics, particularly Bucillamine for infectious diseases, as well as Psilocybin and molecular hydrogen therapeutic programs. The company is leveraging FDA incentives to expedite market entry.
For more information, visit www.ReviveThera.com.
FAQ
What is the size and price of Revive Therapeutics’ (RVVTF) private placement first tranche?
The first tranche consisted of 2.9 million units at $0.021 per unit, raising total gross proceeds of $60,900.
How much debt did Revive Therapeutics (RVVTF) settle in this announcement?
Revive settled $67,400 in debt through the issuance of 3,209,523 units at $0.021 per unit.
What are the terms of the warrants in RVVTF’s private placement?
Each warrant entitles holders to acquire one common share at an exercise price of $0.05 for a period of 36 months following issuance.
When does the hold period expire for RVVTF’s newly issued securities?
The securities are subject to a hold period of four months and one day, expiring on December 9, 2025.
How will Revive Therapeutics use the proceeds from this offering?
The proceeds will be used for working capital and payment of certain trade payables.
“`
Original article, Author: Jam. If you wish to reprint this article, please indicate the source:https://aicnbc.com/6943.html
